DE60336334D1 - Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff - Google Patents

Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff

Info

Publication number: DE60336334D1
Authority: DE; Germany
Prior art keywords: bladder; derivative; hyperactivity; blood; treatment
Prior art date: 2002-11-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60336334T

Other languages

English (en)

Inventor

Toshiyuki Takasu

Shuichi Sato

Masashi Ukai

Tatsuya Maruyama

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Astellas Pharma Inc

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-07

Filing date

2003-11-04

Publication date

2011-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60336334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-04 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2011-04-21 Application granted granted Critical

2011-04-21 Publication of DE60336334D1 publication Critical patent/DE60336334D1/de

2023-11-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DE60336334T 2002-11-07 2003-11-04 Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff Expired - Lifetime DE60336334D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002323792		2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja)	2002-11-07	2003-11-04	酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (1)

Publication Number	Publication Date
DE60336334D1 true DE60336334D1 (de)	2011-04-21

Family

ID=32310425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60336334T Expired - Lifetime DE60336334D1 (de)	2002-11-07	2003-11-04	Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff

Country Status (28)

Country	Link
US (5)	US7750029B2 (de)
EP (1)	EP1559427B1 (de)
JP (1)	JP3815496B2 (de)
KR (1)	KR100967070B1 (de)
CN (1)	CN100406011C (de)
AT (1)	ATE500827T1 (de)
AU (1)	AU2003284700B2 (de)
BE (1)	BE2013C040I2 (de)
BR (1)	BR0316080A (de)
CA (1)	CA2503570C (de)
CY (2)	CY1111399T1 (de)
DE (1)	DE60336334D1 (de)
DK (1)	DK1559427T3 (de)
ES (1)	ES2360353T3 (de)
FR (1)	FR13C0032I2 (de)
HU (1)	HUS1300027I1 (de)
IL (1)	IL168121A (de)
LU (1)	LU92218I2 (de)
MX (1)	MXPA05004925A (de)
NL (1)	NL300599I2 (de)
NO (2)	NO334948B1 (de)
NZ (1)	NZ539577A (de)
PL (1)	PL211687B1 (de)
PT (1)	PT1559427E (de)
RU (1)	RU2321401C2 (de)
SI (1)	SI1559427T1 (de)
WO (1)	WO2004041276A1 (de)
ZA (1)	ZA200503510B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10351271A1 (de) *	2003-10-31	2005-06-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
EP2216021B1 (de)	2007-11-02	2012-10-17	Astellas Pharma Inc.	Pharmazeutische zusammensetzung zur behandlung von blasenhyperaktivität
CA2709727A1 (en) *	2007-12-21	2009-07-02	Astellas Pharma Inc.	Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (es) *	2008-04-04	2009-12-04	Merck & Co Inc	Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
JP5553767B2 (ja) *	2008-11-07	2014-07-16	大日本住友製薬株式会社	新規で有用な下部尿路症状治療剤
WO2010147830A2 (en) *	2009-06-15	2010-12-23	Auspex Pharmaceuticals, Inc.	Aminothiazole modulators of beta-3-adrenoreceptor
JP5849947B2 (ja) *	2010-03-29	2016-02-03	アステラス製薬株式会社	放出制御医薬組成物
WO2011122523A1 (ja) *	2010-03-29	2011-10-06	アステラス製薬株式会社	放出制御医薬組成物
EP2709993A4 (de)	2011-05-18	2015-02-25	Reddys Lab Ltd Dr	Amorphes mirabegron und verfahren für kristalline formen von mirabegron
US9655885B2 (en)	2011-05-18	2017-05-23	Dr. Reddy's Laboratories Ltd.	Amorphous mirabegron and processes for crystal forms of mirabegron
WO2013147134A1 (ja)	2012-03-30	2013-10-03	アステラス製薬株式会社	ミラベグロン含有医薬組成物
EA201590449A1 (ru)	2012-08-31	2015-06-30	Астеллас Фарма Инк.	Перорально вводимая лекарственная композиция
WO2014132270A2 (en) *	2013-02-27	2014-09-04	Msn Laboratories Limited	Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) *	2013-04-17	2013-07-10	苏州永健生物医药有限公司	一种米拉贝隆的合成方法
CN103232368B (zh) *	2013-04-18	2015-08-12	苏州永健生物医药有限公司	一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) *	2013-04-18	2013-07-10	苏州永健生物医药有限公司	一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) *	2013-05-11	2015-12-23	苏州永健生物医药有限公司	(r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
AU2014293141A1 (en) *	2013-07-23	2016-02-18	Serenity Pharmaceuticals Llc	Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
ITMI20131653A1 (it) *	2013-10-07	2015-04-08	Dipharma Francis Srl	Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) *	2013-11-29	2015-05-20	Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации	Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) *	2014-04-08	2015-10-15	Suven Life Sciences Limited	An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) *	2014-04-22	2015-10-29	Calyx Chemicals And Pharmaceuticals Ltd.	Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) *	2014-05-23	2014-09-03	苏州凯瑞医药科技有限公司	一种米拉贝隆的合成方法
CN104016877B (zh) *	2014-06-13	2017-02-15	南京海融制药有限公司	一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) *	2014-09-05	2014-12-24	安徽联创药物化学有限公司	米拉贝隆的合成方法
CN106999538A (zh)	2014-11-20	2017-08-01	阿勒根公司	包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
CN104496841B (zh) *	2014-11-26	2017-01-25	南京工业大学	一种米拉贝隆中间体的合成方法
CN104744292A (zh) *	2015-03-11	2015-07-01	南京工业大学	(r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) *	2015-03-31	2018-06-14	アステラス製薬株式会社	ミラベグロン含有医薬組成物
JP6618736B2 (ja)	2015-09-01	2019-12-11	沢井製薬株式会社	ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) *	2016-08-12	2022-07-15	浙江华海药业股份有限公司	一种米拉贝隆中间体的后处理方法
EP3489224A1 (de)	2017-02-14	2019-05-29	Alfred E. Tiefenbacher (GmbH & Co. KG)	Mirabegron-prodrugs
KR102051132B1 (ko) *	2017-03-17	2019-12-02	주식회사 종근당	미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko)	2017-04-13	2018-06-20	(주) 성운파마코피아	아미드 유도체의 제조방법
CN110730658B (zh)	2017-05-31	2023-01-24	思佰益药业股份有限公司	膀胱过度活动的预防剂或治疗剂
CN117695287A (zh)	2017-06-06	2024-03-15	住友制药(苏州)有限公司	使用维贝隆以治疗膀胱过度活动症
KR102398639B1 (ko)	2017-06-20	2022-05-17	(주) 성운파마코피아	아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (ko)	2017-07-14	2019-01-17	주식회사 대웅제약	약제학적 제제 및 그 제조방법
KR101937713B1 (ko)	2017-07-14	2019-01-14	주식회사 대웅제약	약제학적 제제 및 그 제조방법
JP2022510084A (ja)	2018-12-05	2022-01-26	ウロバントサイエンシズゲーエムベーハー	良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
KR20200117091A (ko)	2019-04-02	2020-10-14	제이투에이치바이오텍 (주)	미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (de)	2020-04-08	2022-03-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Verfahren zur herstellung von mirabegron-enacarbil
CN113816864B (zh) *	2020-06-18	2024-03-29	南京正大天晴制药有限公司	一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko)	2020-12-08	2022-06-15	주식회사 한서켐	미라베그론 α형 결정의 제조방법
EP4338729A1 (de)	2022-09-19	2024-03-20	Sanovel Ilac Sanayi Ve Ticaret A.S.	Tablette mit mirabegron
EP4410279A1 (de)	2023-01-25	2024-08-07	Sanovel Ilac Sanayi Ve Ticaret A.S.	Filmtablette mit mirabegron
KR20240171516A (ko)	2023-05-30	2024-12-09	주식회사 디앤아이바이오	미라베그론 서방정
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release
WO2026010595A1 (en)	2024-07-04	2026-01-08	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A modified release tablet composition comprising mirabegron

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07119189B2 (ja)	1989-09-28	1995-12-20	北陸製薬株式会社	光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en)	1991-04-12	1991-05-29	Fujisawa Pharmaceutical Co	New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en)	1992-02-03	1997-03-18	Fujisawa Pharmaceutical Co	Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja)	1993-04-05	1994-10-21	Fujisawa Pharmaceut Co Ltd	β３−アドレナリン作動薬の新規医薬用途
WO1994025427A1 (en)	1993-04-26	1994-11-10	Fujisawa Pharmaceutical Co., Ltd.	Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (ja)	1994-02-16	1995-08-29	Fujisawa Pharmaceut Co Ltd	β３−アドレナリン作動薬の新規医薬用途
WO1997015549A1 (en)	1995-10-26	1997-05-01	Tokyo Tanabe Company Limited	PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
EP0932401A1 (de) *	1996-07-01	1999-08-04	Sepracor, Inc.	Methoden und zusammensetzungen zur behandlung von harninkontiniez mittels enantiomerishc angereichertem (r,r)-glycopyrrolat
JP4685201B2 (ja)	1996-08-19	2011-05-18	キッセイ薬品工業株式会社	頻尿および尿失禁の予防・治療剤
AU749201B2 (en) *	1997-08-28	2002-06-20	Afferon Corporation	Urinary incontinence therapy
ID23989A (id) *	1997-10-17	2000-06-14	Yamanouchi Pharma Co Ltd	Turunan-turunan amida atau garam-garamnya
PL341221A1 (en)	1997-12-18	2001-03-26	Kissei Pharmaceutical	Derivatives of phenylaminoalkyl carboxylic acid and pharmacological compositions containing them
KR100576131B1 (ko)	1998-04-14	2006-05-03	깃세이 야쿠힌 고교 가부시키가이샤	2메틸프로피온산유도체 및 그 유도체를 함유하는의약조성물
MY126489A (en) *	1998-07-08	2006-10-31	Kissei Pharmaceutical	Phenoxyacetic acid derivatives and medicinal compositions containing the same
AU779411B2 (en)	1999-02-12	2005-01-20	Serono Genetics Institute S.A.	Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) *	1999-10-12	2001-05-16	Merck & Co Inc	Amide derivatives as beta 3 agonists
JP2001114736A (ja) *	1999-10-19	2001-04-24	Kissei Pharmaceut Co Ltd	２−アミノプロパノール誘導体
US20030018061A1 (en)	2000-01-28	2003-01-23	Kohei Ogawa	Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en)	2000-02-28	2000-03-16	Fujisawa Pharmaceutical Co., Ltd.	Aminoalcohol derivatives
AUPQ841300A0 (en)	2000-06-27	2000-07-20	Fujisawa Pharmaceutical Co., Ltd.	New aminoalcohol derivatives
AR035605A1 (es)	2000-12-11	2004-06-16	Bayer Corp	Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en)	2001-10-30	2008-03-11	Astellas Pharma Inc.	α-form or β-form crystal of acetanilide derivative
CA2646729A1 (en) *	2005-03-21	2006-09-28	Dov Pharmaceutical, Inc.	Methods and compositions for the treatment of urinary incontinence

2003
- 2003-11-04 JP JP2004549600A patent/JP3815496B2/ja not_active Expired - Lifetime
- 2003-11-04 US US10/534,290 patent/US7750029B2/en not_active Ceased
- 2003-11-04 AU AU2003284700A patent/AU2003284700B2/en not_active Expired
- 2003-11-04 PT PT03770134T patent/PT1559427E/pt unknown
- 2003-11-04 CA CA2503570A patent/CA2503570C/en not_active Expired - Lifetime
- 2003-11-04 KR KR1020057008158A patent/KR100967070B1/ko not_active Ceased
- 2003-11-04 DE DE60336334T patent/DE60336334D1/de not_active Expired - Lifetime
- 2003-11-04 US US13/542,308 patent/USRE44872E1/en not_active Expired - Lifetime
- 2003-11-04 SI SI200331996T patent/SI1559427T1/sl unknown
- 2003-11-04 DK DK03770134.9T patent/DK1559427T3/da active
- 2003-11-04 CN CNB2003801028894A patent/CN100406011C/zh not_active Ceased
- 2003-11-04 EP EP03770134A patent/EP1559427B1/de not_active Expired - Lifetime
- 2003-11-04 AT AT03770134T patent/ATE500827T1/de active
- 2003-11-04 NZ NZ539577A patent/NZ539577A/en not_active IP Right Cessation
- 2003-11-04 BR BR0316080-7A patent/BR0316080A/pt not_active Application Discontinuation
- 2003-11-04 MX MXPA05004925A patent/MXPA05004925A/es active IP Right Grant
- 2003-11-04 ZA ZA200503510A patent/ZA200503510B/en unknown
- 2003-11-04 PL PL376771A patent/PL211687B1/pl unknown
- 2003-11-04 RU RU2005117367/15A patent/RU2321401C2/ru active
- 2003-11-04 ES ES03770134T patent/ES2360353T3/es not_active Expired - Lifetime
- 2003-11-04 US US10/534,290 patent/US20060115540A1/en active Granted
- 2003-11-04 WO PCT/JP2003/014065 patent/WO2004041276A1/ja not_active Ceased
2005
- 2005-04-19 IL IL168121A patent/IL168121A/en active IP Right Grant
- 2005-06-06 NO NO20052691A patent/NO334948B1/no not_active IP Right Cessation
2008
- 2008-12-12 US US12/333,357 patent/US20090093529A1/en not_active Abandoned
2011
- 2011-04-18 CY CY20111100395T patent/CY1111399T1/el unknown
- 2011-05-27 US US13/117,638 patent/US8835474B2/en not_active Expired - Lifetime
2013
- 2013-06-17 LU LU92218C patent/LU92218I2/fr unknown
- 2013-06-19 FR FR13C0032C patent/FR13C0032I2/fr active Active
- 2013-06-19 HU HUS1300027C patent/HUS1300027I1/hu unknown
- 2013-06-19 CY CY2013023C patent/CY2013023I1/el unknown
- 2013-06-20 BE BE2013C040C patent/BE2013C040I2/fr unknown
- 2013-06-20 NL NL300599C patent/NL300599I2/nl unknown
2015
- 2015-01-19 NO NO2015001C patent/NO2015001I2/no unknown

Also Published As

Publication number	Publication date
AU2003284700A1 (en)	2004-06-07
KR100967070B1 (ko)	2010-07-01
AU2003284700B2 (en)	2009-05-28
DK1559427T3 (da)	2011-04-26
EP1559427A4 (de)	2007-05-30
EP1559427A1 (de)	2005-08-03
NO334948B1 (no)	2014-08-04
CA2503570C (en)	2011-04-19
WO2004041276A1 (ja)	2004-05-21
NO2015001I2 (no)	2015-01-26
ES2360353T3 (es)	2011-06-03
CY2013023I2 (el)	2015-10-07
CA2503570A1 (en)	2004-05-21
HUS1300027I1 (hu)	2016-08-29
NL300599I2 (de)	2017-01-03
ATE500827T1 (de)	2011-03-15
SI1559427T1 (sl)	2011-06-30
RU2005117367A (ru)	2006-01-20
IL168121A (en)	2011-12-29
BE2013C040I2 (de)	2023-03-07
FR13C0032I2 (fr)	2014-03-07
FR13C0032I1 (de)	2013-08-09
KR20050072809A (ko)	2005-07-12
CY2013023I1 (el)	2015-10-07
USRE44872E1 (en)	2014-04-29
JP3815496B2 (ja)	2006-08-30
NO2015001I1 (no)	2015-01-19
CN100406011C (zh)	2008-07-30
US20060115540A1 (en)	2006-06-01
US8835474B2 (en)	2014-09-16
NZ539577A (en)	2007-06-29
PT1559427E (pt)	2011-05-27
EP1559427B1 (de)	2011-03-09
LU92218I9 (de)	2019-01-17
CY1111399T1 (el)	2015-08-05
MXPA05004925A (es)	2005-08-18
US20110230530A1 (en)	2011-09-22
US20090093529A1 (en)	2009-04-09
US7750029B2 (en)	2010-07-06
ZA200503510B (en)	2006-12-27
PL211687B1 (pl)	2012-06-29
NO20052691D0 (no)	2005-06-06
JPWO2004041276A1 (ja)	2006-03-02
PL376771A1 (pl)	2006-01-09
RU2321401C2 (ru)	2008-04-10
LU92218I2 (fr)	2014-01-07
CN1711085A (zh)	2005-12-21
NO20052691L (no)	2005-07-15
BR0316080A (pt)	2005-09-27

Publication	Publication Date	Title
DE60336334D1 (de)	2011-04-21	Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff
ATE524173T1 (de)	2011-09-15	Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
EA200100721A1 (ru)	2002-04-25	Производное габапентина для предупреждения и лечения висцеральной боли
DE60303238D1 (de)	2006-04-06	Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE350375T1 (de)	2007-01-15	17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE69011703D1 (de)	1994-09-29	Therapeutisches Arzneimittel gegen Thrombose und Verfahren zur Herstellung.
DE69916632D1 (de)	2004-05-27	Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE137965T1 (de)	1996-06-15	Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69504949T3 (de)	2004-01-15	Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
ATE289196T1 (de)	2005-03-15	Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
Romer	1980	Pharmacological evaluation of mild analgesics.
ATE330596T1 (de)	2006-07-15	Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60007548D1 (de)	2004-02-05	Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
DE602004023564D1 (de)	2009-11-26	Verwendung von Citrullin zur Herstellung eines Arzneimittels zur Behandlung von ans Altern oder an eine Bestrahlung gebundener intestinaler Insuffizienz
DE602004003173D1 (de)	2006-12-28	Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
ATE239492T1 (de)	2003-05-15	Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE401878T1 (de)	2008-08-15	Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
RU2002135800A (ru)	2004-07-27	Способ определения функционального и метаболического состояния нервной ткани
SU1715369A1 (ru)	1992-02-28	Способ лечени больных хроническим гепатитом
RU2004123072A (ru)	2006-02-10	Способ лечения больных остеоартрозом
RU2000125470A (ru)	2002-08-27	Способ диагностики венозной патологии нижних конечностей
RU2004116493A (ru)	2005-11-10	Способ диагностики нестабильности плечевого сустава
RU2004131111A (ru)	2006-04-10	Способ лечения регенерирующих ран у собак
RU93042070A (ru)	1997-01-27	Способ диагностики посттравматических тромбозов глубоких вен при переломах костей голени
RU95100593A (ru)	1997-01-20	Способ прогнозирования рецидивов язв двенадцатиперстной кишки после ваготомии